# Brentuximab Vedotin
人気のポッドキャストエピソード
更新しました:
brentuximab vedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seagen in the US.
== Medical uses ==
In the United States, brentuximab vedotin is indicated for the treatment of Hodgkin lymphoma, systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, and CD30-expressing mycosis fungoides.
In the European Union, brentuximab vedotin is indicated for the treatment of Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and cutaneous T cell lymphoma.
Precision Medicine for T-Cell Lymphomas: Expert Answers to Your Questions
In this episode, Steven M. Horwitz, MD; Francine Foss, MD; and Barbara Pro, MD, answer questions from an audience of healthcare professionals on topics related to the management of patients with T-cell lymphomas including:
Threshold of CD30 positivity useful to inform brentuximab vedotin use in pa…
Investigating Brentuximab Vedotin for Advanced-Stage Hodgkin Lymphoma With Habte Yimer, MD
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive …
Updates on Trials of Zilovertamab and Brentuximab Vedotin in Lymphomas With Hun Lee, MD
This playlist features episodes that were recorded live at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans by Oncology Data Advisor and ConveyMED. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive …
2.01 Selinexor, ECHELON-2, Parachutes, Tumor-Treating Fields, & MedTwitter
Welcome to season 2! We're starting this season off with a little bit of everything: a critique of the FDA's accelerated approval of selinexor for penta-refractory multiple myeloma; an interview with Dr. John Reneau of Ohio State University on ECHELON-2 (brentuximab vedotin in t-cell lymphomas); an…
Episode 26. Management of Newly Diagnosed Hodgkin's Lymphoma
In this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University.
Link for our Blood Cancer Talks Survey: https://bit.ly/BCTS
Here are the key trials we discu…
ポッドキャスト検索エンジン
当社の Web サイトを使用して、人、場所、トピックごとに 3,821,009 ポッドキャストや 195,286,681 エピソードを検索できます。
知識への投資は最も大きな利益をもたらす。だから私はポッドキャストを聴く。
‐ Benjamin "Llamacorn" Franklin
